Thomas McCourt has been at the helm of Ironwood Pharmaceuticals since June 2021, bringing over two decades of experience in the pharmaceutical industry. Under his leadership, the company has focused on developing treatments for gastrointestinal diseases, notably with its successful...

Thomas McCourt has been at the helm of Ironwood Pharmaceuticals since June 2021, bringing over two decades of experience in the pharmaceutical industry. Under his leadership, the company has focused on developing treatments for gastrointestinal diseases, notably with its successful product LINZESS. McCourt previously worked at Pliant Therapeutics, where he continued to build his expertise in the life sciences sector. He was born on June 7, 1957, and while his educational background isn't specified, his practical know-how in managing complex organizations stands out. In 2023, he received a total compensation of about $7.58 million, reflecting a performance-based structure that ties his pay to the success of the company. Interestingly, his insider trading history shows significant actions, with his stock holdings having peaked around mid-2021, reaching over $8 million, and fluctuating with market trends thereafter. This illustrates his commitment not only to his role as CEO but also to aligning his interests with those of shareholders.